MINAPHARM Pharmaceuticals (EGX:MIPH)
Egypt · Delayed Price · Currency is EGP 315.56
-10.63 (-3.26%)
At close: Oct 23, 2025
MINAPHARM Pharmaceuticals Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 6,936 | 5,665 | 3,892 | 3,621 | 3,005 | 2,361 | Upgrade | |
Revenue Growth (YoY) | 77.12% | 45.55% | 7.50% | 20.47% | 27.29% | 15.11% | Upgrade |
Cost of Revenue | 4,215 | 3,728 | 2,640 | 2,124 | 1,820 | 1,457 | Upgrade |
Gross Profit | 2,721 | 1,937 | 1,252 | 1,496 | 1,185 | 904.48 | Upgrade |
Selling, General & Admin | 1,055 | 828.91 | 718.51 | 474.95 | 392.79 | 326.6 | Upgrade |
Research & Development | 167.54 | 131.26 | 151.27 | 59.35 | 45.84 | 39.08 | Upgrade |
Operating Expenses | 1,263 | 1,003 | 876.91 | 531.63 | 431.37 | 365.68 | Upgrade |
Operating Income | 1,459 | 933.85 | 374.66 | 964.74 | 753.96 | 538.8 | Upgrade |
Interest Expense | -712.71 | -593.68 | -254.46 | -62.17 | -48.84 | -69.3 | Upgrade |
Interest & Investment Income | 61.59 | 46.56 | 14.06 | 9.55 | 5.08 | 5.8 | Upgrade |
Currency Exchange Gain (Loss) | -89.6 | 10.67 | -37.3 | 37.52 | -1.76 | 1.64 | Upgrade |
Other Non Operating Income (Expenses) | -229.69 | -117.27 | -63.76 | -69.3 | -40.66 | -45 | Upgrade |
EBT Excluding Unusual Items | 488.14 | 280.12 | 33.2 | 880.34 | 667.79 | 431.95 | Upgrade |
Gain (Loss) on Sale of Assets | -0.2 | -0.45 | -0.17 | - | 0.46 | - | Upgrade |
Pretax Income | 487.94 | 279.67 | 33.03 | 880.34 | 668.25 | 431.95 | Upgrade |
Income Tax Expense | 231.51 | 118.57 | 10.67 | 249.44 | 193.38 | 121.27 | Upgrade |
Earnings From Continuing Operations | 256.44 | 161.11 | 22.36 | 630.89 | 474.87 | 310.68 | Upgrade |
Minority Interest in Earnings | 4.85 | -4.04 | -54.35 | -18.23 | -8.46 | -9.9 | Upgrade |
Net Income | 261.29 | 157.07 | -31.99 | 612.66 | 466.41 | 300.78 | Upgrade |
Preferred Dividends & Other Adjustments | 40.29 | 28.91 | 23.4 | 22.75 | 18.7 | 15.53 | Upgrade |
Net Income to Common | 221 | 128.15 | -55.39 | 589.91 | 447.71 | 285.25 | Upgrade |
Net Income Growth | - | - | - | 31.36% | 55.06% | 113.18% | Upgrade |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 12 | 12 | Upgrade |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 12 | 12 | Upgrade |
Shares Change (YoY) | - | - | -3.57% | -6.67% | - | - | Upgrade |
EPS (Basic) | 19.97 | 11.58 | -5.01 | 51.41 | 36.42 | 23.20 | Upgrade |
EPS (Diluted) | 19.97 | 11.58 | -5.01 | 51.41 | 36.42 | 23.20 | Upgrade |
EPS Growth | - | - | - | 41.17% | 56.95% | 102.17% | Upgrade |
Free Cash Flow | -425.99 | -697.45 | -1,292 | -598.45 | -180.6 | 286.84 | Upgrade |
Free Cash Flow Per Share | -38.50 | -63.04 | -116.81 | -52.16 | -14.69 | 23.33 | Upgrade |
Dividend Per Share | 2.500 | 2.500 | 1.650 | 2.800 | 2.922 | 2.700 | Upgrade |
Dividend Growth | 51.52% | 51.52% | -41.07% | -4.17% | 8.21% | - | Upgrade |
Gross Margin | 39.23% | 34.19% | 32.16% | 41.33% | 39.44% | 38.31% | Upgrade |
Operating Margin | 21.03% | 16.48% | 9.63% | 26.65% | 25.09% | 22.82% | Upgrade |
Profit Margin | 3.19% | 2.26% | -1.42% | 16.29% | 14.90% | 12.08% | Upgrade |
Free Cash Flow Margin | -6.14% | -12.31% | -33.21% | -16.53% | -6.01% | 12.15% | Upgrade |
EBITDA | 1,744 | 1,172 | 536.04 | 1,086 | 835.91 | 621.7 | Upgrade |
EBITDA Margin | 25.14% | 20.69% | 13.77% | 29.99% | 27.81% | 26.33% | Upgrade |
D&A For EBITDA | 285.16 | 238.38 | 161.38 | 121.14 | 81.95 | 82.9 | Upgrade |
EBIT | 1,459 | 933.85 | 374.66 | 964.74 | 753.96 | 538.8 | Upgrade |
EBIT Margin | 21.03% | 16.48% | 9.63% | 26.65% | 25.09% | 22.82% | Upgrade |
Effective Tax Rate | 47.45% | 42.39% | 32.29% | 28.34% | 28.94% | 28.07% | Upgrade |
Advertising Expenses | - | - | - | 8.4 | 15.38 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.